Does Rallies show 13F holders for DERM?

Yes. Rallies tracks hedge fund and 13F ownership data for DERM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DERM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DERM. It does not provide personalized investment advice.

DERM (Journey Medical Corporation Common Stock) Stock Analysis - Hedge Fund Holdings

Journey Medical Corporation Common Stock (DERM) is a publicly traded Healthcare sector company. As of May 21, 2026, DERM trades at $6.17 with a market cap of $172.09M and a P/E ratio of -16.63. DERM moved +0.08% today. Year to date, DERM is -13.34%; over the trailing twelve months it is -10.32%. Its 52-week range spans $3.54 to $9.56. Analyst consensus is strong buy with an average price target of $13.50. Rallies surfaces DERM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DERM stock?

Hedge funds tracked by Rallies that own DERM include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Journey Medical Corporation Common Stock.

DERM Key Metrics

Key financial metrics for DERM
Metric	Value
Price	$6.17
Market Cap	$172.09M
P/E Ratio	-16.63
EPS	$-0.37
Dividend Yield	0.00%
52-Week High	$9.56
52-Week Low	$3.54
Volume	0
Avg Volume	0
Revenue (TTM)	$64.68M
Net Income	$-9.59M
Gross Margin	65.44%

Top Hedge Funds Holding DERM

Renaissance Technologies holds 236.00K shares of DERM, changed -12.01% as of Dec 31, 2024.
Citadel Advisors holds 44.57K shares of DERM, changed +292.43% as of Dec 31, 2024.

Latest DERM News

Journey Medical Reports Q1 Loss Narrowing From $0.18, Revenue Tops Forecasts — May 14, 2026
Journey Medical Secures Third GPO Contract to Cover 150M Commercial Lives for Emrosi — Apr 21, 2026
Journey Medical Achieves 11% Product Revenue Growth, MROS Sales Hit $14.7M in Nine Months — Mar 26, 2026
Journey Medical Forecasts Q4 Revenue of $18.9M and 6¢ Loss Ahead of Earnings — Mar 24, 2026

Recent DERM Insider Trades

Maraoui Claude sold 4.83K (~$33.06K) on May 2, 2025.
Benesch Joseph sold 2.41K (~$16.48K) on May 2, 2025.
Alloush Ramsey sold 2.86K (~$19.54K) on May 2, 2025.

DERM Analyst Consensus

4 analysts cover DERM: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.50.

Common questions about DERM

Who owns DERM stock?: Hedge funds tracked by Rallies that own DERM include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Journey Medical Corporation Common Stock.
Does Rallies show 13F holders for DERM?: Yes. Rallies tracks hedge fund and 13F ownership data for DERM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DERM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DERM. It does not provide personalized investment advice.